Desq Long
Sign in

Company

LIGAND PHARMACEUTICALS INC

LGND · CIK 0000886163

SEC FORM 4
$34,327.50

LIGAND PHARMACEUTICALS INC (LGND)

Disposition (code F) of 115 shares at $298.5 per share.

Reporting Person Zimmermann Martine · Transaction Code F

Traded Sep 22, 2026 · Disclosed Sep 24, 2026

Source: SEC Form 4 · 0002001011-26-000142 · filed 2026-09-24 · View filing →

SEC FORM 4
$342,000.00

LIGAND PHARMACEUTICALS INC (LGND)

Sale of 1,200 shares at $285.0 per share.

Reporting Person Zimmermann Martine · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 14, 2026

Source: SEC Form 4 · 0002001011-26-000140 · filed 2026-09-14 · View filing →

SEC FORM 4
$85,195.62

LIGAND PHARMACEUTICALS INC (LGND)

Sale of 300 shares at $283.9854 per share.

Reporting Person Reardon Andrew · Officer Title CLO & Secretary · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 8, 2026

Source: SEC Form 4 · 0002001011-26-000137 · filed 2026-09-08 · View filing →

SEC FORM 4
$513,300.78

LIGAND PHARMACEUTICALS INC (LGND)

Sale of 1,800 shares at $285.1671 per share.

Reporting Person Reardon Andrew · Officer Title CLO & Secretary · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 8, 2026

Source: SEC Form 4 · 0002001011-26-000137 · filed 2026-09-08 · View filing →

SEC FORM 4
$605,649.07

LIGAND PHARMACEUTICALS INC (LGND)

Sale of 2,115 shares at $286.3589 per share.

Reporting Person Reardon Andrew · Officer Title CLO & Secretary · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 8, 2026

Source: SEC Form 4 · 0002001011-26-000137 · filed 2026-09-08 · View filing →

SEC FORM 4
$110,697.24

LIGAND PHARMACEUTICALS INC (LGND)

Sale of 385 shares at $287.5253 per share.

Reporting Person Reardon Andrew · Officer Title CLO & Secretary · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 8, 2026

Source: SEC Form 4 · 0002001011-26-000137 · filed 2026-09-08 · View filing →

SEC FORM 4
$115,591.68

LIGAND PHARMACEUTICALS INC (LGND)

Sale of 400 shares at $288.9792 per share.

Reporting Person Reardon Andrew · Officer Title CLO & Secretary · Transaction Code S

Traded Sep 3, 2026 · Disclosed Sep 8, 2026

Source: SEC Form 4 · 0002001011-26-000137 · filed 2026-09-08 · View filing →

SEC FORM 4
$316,475.28

LIGAND PHARMACEUTICALS INC (LGND)

Acquisition (code M) of 6,138 shares at $51.56 per share.

Reporting Person Haas Jason · Transaction Code M

Traded Aug 12, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002001011-26-000114 · filed 2026-08-14 · View filing →

SEC FORM 4
$2,090,062.08

LIGAND PHARMACEUTICALS INC (LGND)

Sale of 7,138 shares at $292.8078 per share.

Reporting Person Haas Jason · Transaction Code S

Traded Aug 12, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002001011-26-000114 · filed 2026-08-14 · View filing →

SEC FORM 4
$854,898.36

LIGAND PHARMACEUTICALS INC (LGND)

Acquisition (code M) of 16,179 shares at $52.84 per share.

Reporting Person Espinoza Octavio · Officer Title Chief Financial Officer · Transaction Code M

Traded Aug 12, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002001011-26-000115 · filed 2026-08-14 · View filing →

SEC FORM 4
$145,262.96

LIGAND PHARMACEUTICALS INC (LGND)

Acquisition (code M) of 2,074 shares at $70.04 per share.

Reporting Person Espinoza Octavio · Officer Title Chief Financial Officer · Transaction Code M

Traded Aug 12, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002001011-26-000115 · filed 2026-08-14 · View filing →

SEC FORM 4
$159,946.75

LIGAND PHARMACEUTICALS INC (LGND)

Acquisition (code M) of 2,869 shares at $55.75 per share.

Reporting Person Espinoza Octavio · Officer Title Chief Financial Officer · Transaction Code M

Traded Aug 12, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002001011-26-000115 · filed 2026-08-14 · View filing →

SEC FORM 4
$410,324.62

LIGAND PHARMACEUTICALS INC (LGND)

Acquisition (code M) of 7,171 shares at $57.22 per share.

Reporting Person Espinoza Octavio · Officer Title Chief Financial Officer · Transaction Code M

Traded Aug 12, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002001011-26-000115 · filed 2026-08-14 · View filing →

SEC FORM 4
$230,141.52

LIGAND PHARMACEUTICALS INC (LGND)

Acquisition (code M) of 3,348 shares at $68.74 per share.

Reporting Person Espinoza Octavio · Officer Title Chief Financial Officer · Transaction Code M

Traded Aug 12, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002001011-26-000115 · filed 2026-08-14 · View filing →

SEC FORM 4
$9,241,228.66

LIGAND PHARMACEUTICALS INC (LGND)

Sale of 31,641 shares at $292.065 per share.

Reporting Person Espinoza Octavio · Officer Title Chief Financial Officer · Transaction Code S

Traded Aug 12, 2026 · Disclosed Aug 14, 2026

Source: SEC Form 4 · 0002001011-26-000115 · filed 2026-08-14 · View filing →